Beneficial Ownership Report · SCHEDULE 13G/A
Moderna, Inc.
MRNANASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- MODERNA INC
- Company CIK
- 0001682852
- Street
- 325 BINNEY STREET
- City
- CAMBRIDGE
- State / country code
- MA
- Postal code
- 02142
Statement details
- Amendment number
- 3
- Security class
- COMMON STOCK
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(b)
Reporting person 1
- Name
- FMR LLC
- Citizenship / organization
- DE
- Reporting person type
- HC
- Aggregate amount owned
- 58,929,948.15
- Percent of class
- 14.8
- Sole voting power
- 58,374,817.50
- Shared voting power
- 0.00
- Sole dispositive power
- 58,929,948.15
- Shared dispositive power
- 0.00
Reporting person 2
- Name
- Abigail P. Johnson
- Citizenship / organization
- X1
- Reporting person type
- IN
- Aggregate amount owned
- 58,929,948.15
- Percent of class
- 14.8
- Sole voting power
- 0.00
- Shared voting power
- 0.00
- Sole dispositive power
- 58,929,948.15
- Shared dispositive power
- 0.00
Item 1
Issuer
MODERNA INC
Principal executive office address
325 BINNEY STREET,CAMBRIDGE,MA,US,02142
Item 2
Citizenship
Not applicable
Filing person
FMR LLC
Principal business or residence address
245 Summer Street, Boston, Massachusetts 02210
Item 3
Not applicable indication
N
Type of filing person
HC
Item 4
Percent of class
14.8
Amount beneficially owned
58929948.15
Sole voting power
Please see the responses to Items 5 and 6 on the cover page.
Shared voting power
0.00
Sole dispositive power
58929948.15
Shared dispositive power
0.00
Item 5
Not applicable indication
Y
Ownership of 5% or less
N
Item 6
Not applicable indication
N
Ownership on behalf of another person
One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of MODERNA INC. No one other person's interest in the COMMON STOCK of MODERNA INC is more than five percent of the total outstanding COMMON STOCK.
Item 7
Not applicable indication
N
Subsidiaries
See attached Exhibit 99.
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Exhibits
Please see Exhibit 99 for 13d-1(k) (1) agreement.
Signature comments
* This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
Signature 1
- Reporting person
- FMR LLC
- Signed
- Stephanie J. Brown
- Title
- Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
- Date
- 11/04/2026
Signature 2
- Reporting person
- Abigail P. Johnson
- Signed
- Stephanie J. Brown
- Title
- Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
- Date
- 11/04/2026
Filed exhibits
- EX-99 ↗exhibit99.txt
Company context
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna’s mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more. With a global team and a unique culture, driven by the company’s values and mindsets, Moderna’s mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.
Current securities
Recent company filings
- Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet ArrangementNov 16, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsNov 13, 2026
- 10-Q filingNov 6, 2026
- Results of Operations and Financial ConditionNov 6, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureSep 30, 2026